Army Corps of Engineers building critical fish passage in Niagara River
BUFFALO — A project is underway to help one of the Niagara River and Lake Erie's most important fish thrive despite decades of manmade impacts to the ecosystem.
The effort is being undertaken by the U.S. Army Corps of Engineers, Buffalo District, in a cross-agency partnership with the U.S. Environmental Protection Agency.
With funding from the EPA's Great Lakes Restoration Initiative, the Army Corps is beginning work to build a 700-foot-long fish passage at the City of Buffalo's Freedom Park to help emerald shiners overcome the velocity of the Niagara River and move upstream after spawning, providing a critical food source for larger fish and wildlife, offering sustenance for the local community, and contributing to goals for delisting the Niagara River as a Great Lakes Area of Concern (AOC).
Contractors were set to mobilize at Freedom Park on March 31 to prepare to begin work.
'A healthy ecosystem is vital to the nation's waterways, with the emerald shiner playing a big role,' said Lt. Col. Robert Burnham, USACE Buffalo District commander. 'Working with the EPA and our partners, we're excited to bring this project to fruition and ensure this little fish with a big impact can thrive in the Niagara River.'
The Buffalo District will work to minimize impacts of construction and ensure safety for users of Freedom Park, with some portions of the park being closed during construction and access to Bird Island Pier closed on a limited basis as needed. The majority of the project area will be fenced off.
The emerald shiner is a small, but critical prey fish at the base of the food web in the Niagara River and Lake Erie. It is often overlooked due to its size and seeming abundance, but the fish's population is threatened by hydraulic barriers from hardened shorelines like the seawall along Freedom Park. Studies conducted by USACE, the University at Buffalo, and SUNY Buffalo State University identified this stretch of the Niagara River as having water velocity too fast for shiners to swim as they attempt to move upstream after spawning.
The USACE Buffalo District constructed a demonstration project at Freedom Park in 2022 to test the experimental designs for the fish passage. Funded by the GLRI, the $1.6 million demonstration project entailed repairs to a 78-foot span of the park's existing seawall and installation of metal baffles designed to withstand the forces of the mighty Niagara River, reduce water velocity, and ensure the passage of shiners after spawning. All three measures were hugely successful and inspired final plans for the current project.
The USACE Buffalo District awarded an $11.8 million contract to Buffalo-based Bidco Marine Group on Sept. 16 to construct the 'full' fish passage for emerald shiners.
The 'full' structure will span 700 feet along the seawall at Freedom Park, from the middle of the park to the start of the Bird Island Pier which runs along the Black Rock Canal under the Peace Bridge. Construction will include repairs to the timber crib wall, installation of a steel plate within two feet above and below the typical waterline, concrete surface repair, and filling voids with grout and concrete. Once repairs to the wall are made, metal baffles will be attached. The baffles will be filled with concrete – a design selected from different baffle types tested during the demonstration project.
Construction is planned to be completed by December 2026. The work will be conducted on shore and in the water along the seawall. A portion of Freedom Park will be closed during construction, with fencing and signage placed to ensure safe operations and protect park visitors.
The project is 100% federally funded by the EPA through the Great Lakes Restoration Initiative.
Niagara River Area of Concern
The Niagara River is a binational Area of Concern that includes the entire Niagara River.
At the beginning of the 20th century, the cities of Buffalo, Tonawanda and Niagara Falls received significant expansions in steel and chemical manufacturing, as well as grain milling along the shoreline of the Niagara River. This was due to open land and the availability of electricity and cooling water from Niagara Falls. Steel, petrochemical, and chemical manufacturing industries flourished along the Niagara River into the late 1970s. Subsequently, they declined, leaving behind a legacy of contamination and impairments.
A Niagara River AOC Habitat Restoration Plan finalized in 2019 outlines management actions necessary to remove the Loss of Fish and Wildlife Habitat BUI. BUIs are designations given by the International Joint Commission representing different types of significant environmental degradation. An interim success of remediation and restoration work is being completed within the Niagara River AOC to address designated BUIs. As cleanup work is completed, and monitoring demonstrates sufficient environmental health improvements, BUIs can gradually be removed.
As a critical prey species, the threat to emerald shiner populations are part of the Loss of Fish and Wildlife Habitat BUI for the AOC. A healthy shiner population feeds a healthy population of larger fish and birds. Walleye, a fish that sustains local recreational and commercial fishing communities, and the common tern, a state-listed rare bird, feed on shiners. Shiners are also used by humans as bait fish and for consumption. Improving passage for shiners helps restore fish communities and contributes to removal of the BUI.
The New York State Department of Environmental Conservation is the Niagara River remedial action plan coordinator and with input from agencies and local partners, selected this project as a management action for the Loss of Fish and Wildlife Habitat BUI.
More information on the Niagara River AOC is available at: https://www.epa.gov/great-lakes-aocs/niagara-river-aoc-0 and https://dec.ny.gov/nature/waterbodies/lakes-rivers/great-lakes/areas-of-concern/niagara-river-area-of-concern.
Great Lakes Restoration Initiative
The Great Lakes Restoration Initiative is a non-regulatory program to accelerate efforts to protect and restore the largest system of fresh surface water in the world. The EPA leads a group of 16 federal agencies in the GLRI Interagency Task Force and Regional Working Group, strategically targeting the biggest threats to the Great Lakes ecosystem. GLRI Action Plan III was developed with input from states, tribes, local governments, universities, business, and others. It outlines priorities and goals for the GLRI for fiscal years 2020–2024, working to accelerate environmental progress in five focus areas:
• Toxic substances and areas of concern
• Invasive species
• Nonpoint Source Pollution impacts on nearshore health
• Habitats and species
• Foundations for future restoration actions
More information on the GLRI is available at: https://www.glri.us/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
How humpback whales are playfully communicating with humans, according to scientists
Humpback whales may be communicating with humans in a playful way, according to researchers who have been studying the marine mammals' behavior. Researchers from the SETI Institute, a Silicon Valley-based nonprofit research organization, documented humpback whales producing large bubble rings -- similar to the rings humans can produce while blowing smoke -- during friendly interactions with humans, they noted in a paper published last month in the journal Marine Mammal Science. MORE: 50th anniversary of 'Jaws': How the film impacted public perception of sharks This behavior, while little studied, could represent play or communication, the scientists said. Humpback whales were already known to use bubbles to corral, and males have been observed creating bubble trails or bursts when competing for a female mate, according to the SETI Institute. But new observations that appear to show humpback whales producing bubble rings during friendly encounters with humans contributes to a broader goal of studying non-human intelligence, the scientists said. Studying non-human intelligence can aid in the search for extraterrestrial life, the researchers said. The SETI whale team is aiming to develop filters that aid in parsing cosmic signals for signs of extraterrestrial life by studying intelligent, non-terrestrial -- or aquatic -- nonhuman communication systems, according to the research organization. "Because of current limitations on technology, an important assumption of the search for extraterrestrial intelligence is that extraterrestrial intelligence and life will be interested in making contact and so target human receivers," Laurance Doyle, SETI Institute scientist and co-author on the paper, said in a statement. "This important assumption is certainly supported by the independent evolution of curious behavior in humpback whales." Researchers analyzed 12 bubble ring–production episodes involving 39 rings made by 11 individual whales, they said. They determined the whales are blowing bubble rings in the direction of humans in an apparent attempt to playfully interact, observe humans' response and engage in some form of communication, Fred Sharpe, a co-author of the paper, said in a statement. "Humpback whales live in complex societies, are acoustically diverse, use bubble tools and assist other species being harassed by predators," Sharpe, who is a legacy board member of the Alaska Whale Foundation, said. MORE: Scientists discover how whales can sing under water and how shipping noise can disrupt communication Humpback whales often display "inquisitive, friendly behavior" toward boats and humans, according to Jodi Frediani, a marine wildlife photographer and paper co-author. "We've now located a dozen whales from populations around the world, the majority of which have voluntarily approached boats and swimmers blowing bubble rings during these episodes of curious behavior," Frediani said. For decades, scientists have been studying how intelligent marine mammals such as whales and dolphins communicate with each other. In 2021, researchers from the SETI Institute recorded a conversation with a humpback whale named Twain by playing whale calls through an underwater speaker. MORE: Ocean scientists concerned over uptick of whale deaths on Northeast coasts Last year, another group of researchers at the University of Southern Denmark discovered how baleen whales are able to sing underwater. Also in 2024, SETI Institute researchers discovered that whale calls made during bubble feeding events were likely a way for whales to issue instructions to the group.
2 hours ago
How humpback whales are playfully communicating with humans, according to scientists
Humpback whales may be communicating with humans in a playful way, according to researchers who have been studying the marine mammals' behavior. Researchers from the SETI Institute, a Silicon Valley-based nonprofit research organization, documented humpback whales producing large bubble rings -- similar to the rings humans can produce while blowing smoke -- during friendly interactions with humans, they noted in a paper published last month in the journal Marine Mammal Science. This behavior, while little studied, could represent play or communication, the scientists said. Humpback whales were already known to use bubbles to corral, and males have been observed creating bubble trails or bursts when competing for a female mate, according to the SETI Institute. But new observations that appear to show humpback whales producing bubble rings during friendly encounters with humans contributes to a broader goal of studying non-human intelligence, the scientists said. Studying non-human intelligence can aid in the search for extraterrestrial life, the researchers said. The SETI whale team is aiming to develop filters that aid in parsing cosmic signals for signs of extraterrestrial life by studying intelligent, non-terrestrial -- or aquatic -- nonhuman communication systems, according to the research organization. "Because of current limitations on technology, an important assumption of the search for extraterrestrial intelligence is that extraterrestrial intelligence and life will be interested in making contact and so target human receivers," Laurance Doyle, SETI Institute scientist and co-author on the paper, said in a statement. "This important assumption is certainly supported by the independent evolution of curious behavior in humpback whales." Researchers analyzed 12 bubble ring–production episodes involving 39 rings made by 11 individual whales, they said. They determined the whales are blowing bubble rings in the direction of humans in an apparent attempt to playfully interact, observe humans' response and engage in some form of communication, Fred Sharpe, a co-author of the paper, said in a statement. "Humpback whales live in complex societies, are acoustically diverse, use bubble tools and assist other species being harassed by predators," Sharpe, who is a legacy board member of the Alaska Whale Foundation, said. Humpback whales often display "inquisitive, friendly behavior" toward boats and humans, according to Jodi Frediani, a marine wildlife photographer and paper co-author. "We've now located a dozen whales from populations around the world, the majority of which have voluntarily approached boats and swimmers blowing bubble rings during these episodes of curious behavior," Frediani said. For decades, scientists have been studying how intelligent marine mammals such as whales and dolphins communicate with each other. In 2021, researchers from the SETI Institute recorded a conversation with a humpback whale named Twain by playing whale calls through an underwater speaker. Last year, another group of researchers at the University of Southern Denmark discovered how baleen whales are able to sing underwater. Also in 2024, SETI Institute researchers discovered that whale calls made during bubble feeding events were likely a way for whales to issue instructions to the group.
Yahoo
3 hours ago
- Yahoo
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i
Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host conference call and webcast today at 8:00 A.M. ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), today announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog engineered for class-leading durability, potency, and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i. In the study, MET-233i demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36, a 19-day observed half-life supporting once-monthly dosing, and a favorable tolerability profile with no safety signals. 'We are excited by these impressive results from MET-233i, which demonstrate exceptional efficacy with no safety signals, and enable the potential first monthly multi-NuSH combination,' said Steve Marso, M.D., Chief Medical Officer of Metsera. 'We observed five-week body weight loss comparable to that of leading GLP-1-based medicines, and we identified efficacious starting doses with placebo-like tolerability. These data position MET-233i as a potential best-in-class amylin and support a category-leading profile in combination with MET-097i.' The randomized, placebo-controlled, double-blind Phase 1 trial was designed to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous MET-233i in 80 participants with overweight or obesity without type 2 diabetes. MET-233i was evaluated at single doses from 0.15 mg to 2.4 mg, and multiple doses from 0.15 mg to 1.2 mg given once weekly over five weeks without titration. The trial population was broadly balanced in gender between MET-233i and placebo and had a mean baseline body mass index of approximately 32. Topline results from the Phase 1 trial include: Dose-linear pharmacokinetics with an observed half-life of 19 days from dose to 50% of Cmax. This represents the most durable pharmacokinetic profile of any known amylin analog and supports the potential for once-monthly dosing with simplified titration. MET-233i's exposure profile after multiple doses matched that of MET-097i, supporting combinability as a potential first-in-category once-monthly multi-NuSH combination. These data further substantiate HALO™, Metsera's proprietary, novel peptide stabilization and lipidation platform technology. Body weight loss up to 8.4%. Body weight loss was dose-dependent, ranging up to a placebo-subtracted mean of 8.4% at Day 36 after five weekly doses of 1.2 mg, with individual responses as high as 10.2%. In the single ascending dose (SAD) portion of the trial, substantial weight loss was maintained more than four weeks after dosing, supported by the ultra-long pharmacokinetics observed for MET-233i. Favorable tolerability results. Gastrointestinal adverse events in the multiple ascending dose (MAD) portion of the trial were all mild, dose-dependent, and primarily confined to the first week of dosing, implying rapid onset of tolerance despite a three-fold accumulation of exposure over five weeks. Anticipated starting doses of 0.15 mg and 0.3 mg demonstrated tolerability results comparable to placebo in both the SAD and the MAD portions of the trial. No safety signals. There were no severe or serious adverse events observed in the SAD or MAD portion of the trial to date. 'Amylin agonism has emerged as a central therapeutic mechanism for metabolic diseases, but candidates in development have been limited to weekly dosing,' said Professor Carel le Roux, Director of the Metabolic Medicine Group and Chair in Experimental Pathology at University College Dublin. 'The durability and efficacy of MET-233i in this trial, along with its combinability with Metsera's GLP-1 RA, make it the potential first monthly multi-NuSH combination candidate for patients seeking greater levels of well-tolerated weight loss with a more convenient dosing schedule.'Next StepsBased on these positive topline data, Metsera is rapidly advancing MET-233i as a monotherapy and in combination with MET-097i: An ongoing monotherapy trial evaluates 12 weekly doses of MET-233i with dose titration, followed by an exposure-matched monthly dose at week 13. Topline data from this trial are expected in late 2025. Metsera has extended an ongoing co-administration trial of MET-233i and MET-097i to twelve weeks, with topline data expected by year-end 2025 or early 2026. The Company also expects to report topline clinical data from its ultra-long acting GIP receptor agonist, MET-034i, in combination with MET-097i, in late 2025. We anticipate that MET-034i will be the third peptide engineered with Metsera's HALO™ platform to enter clinical Call and Webcast InformationMetsera will host a conference call and webcast today, June 9, 2025, at 8:00 A.M. Eastern Time to discuss the Phase 1 clinical trial of MET-233i. A live webcast of the call and a replay will be available on the Events page in the Investors & News section of the Metsera website at To access the call by phone, participants should visit this link to receive dial-in details: About MET-233i MET-233i is an ultra-long acting, subcutaneously injectable monthly amylin analog engineered for class-leading durability, potency, and combinability in solution with Metsera's fully-biased, ultra-long acting GLP-1 RA candidate MET-097i, with matched solubility parameters and observed half-lives. MET-233i is being explored in clinical studies as a monotherapy and in combination with MET-097i. Metsera is developing the combination of MET-233i and MET-097i via the FDA biologic pathway with the intent to pursue the combination's regulatory approval in the United States under a Metsera's HALO™ peptide stabilization and lipidation platformHALO™ is Metsera's novel peptide stabilization and lipidation platform technology that enables peptides to bind simultaneously to albumin and to a drug target, designed to facilitate a half-life approaching that of albumin and exceeding that of other NuSH peptides. This ultra-long half-life may enable monthly dosing, improved tolerability, and improved Metsera, is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York City. For more information, please visit us at and follow us on LinkedIn and X. Metsera may use its website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors & News section of its website at In addition, you may sign up to automatically receive email alerts and other information about the Company by using the 'Email Alerts' option on the Investors & Media page and submitting your email address. Forward Looking StatementsThis press release includes 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to the timelines, design and results of the Company's clinical trials and data releases; the Company's product candidate pipeline and milestone events; potential benefits of treatment with the Company's product candidates; and anticipated market opportunity and strategy. When used herein, words including 'anticipate,' 'believe,' 'can,' 'continue,' 'could,' 'designed,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All forward-looking statements are based upon the Company's current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, our limited operating history; our ability to generate revenue or become profitable; failure to obtain additional capital when needed on acceptable terms or at all; raising additional capital may cause dilution to our stockholders or require us to relinquish rights to our technologies or product candidates; our dependence on the success of our product candidates; risks associated with preclinical and clinical development; difficulties or delays in the commencement or completion, or the termination or suspension, of clinical trials; our ability to timely enroll patients in our clinical trials; if our current or future product candidates are associated with side effects, adverse events or other properties or safety risks; risks associated with the regulatory approval processes of the FDA and comparable foreign authorities; risks associated with conducting clinical trials and preclinical studies outside of the United States; our reliance on third parties to conduct clinical trials and preclinical studies; our reliance on third parties for the manufacture and shipping of our product candidates; risks associated with our license and collaboration agreements and future strategic alliances; significant competition in our industry; product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated; our success is dependent on our ability to attract and retain highly qualified management and other clinical and scientific personal; if we or our licensors are unable to obtain, maintain, defend and enforce patent or other intellectual property protection for our current or future product candidates or technology; risks associated with our common stock and the other important factors discussed under the caption 'Risk Factors' in its filings with the Securities and Exchange Commission, including in its Annual Report on Form 10-K for the year ended December 31, 2024 and its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, which are accessible on the SEC's website at and the Investors section of the Company's website at Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause the Company's views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release. Contact:Jono EmmettMetseramedia@
